KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Debt to Equity (2018 - 2025)

Historic Debt to Equity for Castle Biosciences (CSTL) over the last 6 years, with Q3 2025 value amounting to $0.02.

  • Castle Biosciences' Debt to Equity fell 524.44% to $0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year decrease of 524.44%. This contributed to the annual value of $0.02 for FY2024, which is N/A changed from last year.
  • Castle Biosciences' Debt to Equity amounted to $0.02 in Q3 2025, which was down 524.44% from $0.02 recorded in Q2 2025.
  • Castle Biosciences' Debt to Equity's 5-year high stood at $0.05 during Q1 2022, with a 5-year trough of $0.02 in Q3 2025.
  • Moreover, its 3-year median value for Debt to Equity was $0.02 (2024), whereas its average is $0.03.
  • Data for Castle Biosciences' Debt to Equity shows a peak YoY increase of 524.44% (in 2025) and a maximum YoY decrease of 830.24% (in 2025) over the last 5 years.
  • Castle Biosciences' Debt to Equity (Quarter) stood at $0.05 in 2022, then crashed by 58.1% to $0.02 in 2024, then dropped by 2.15% to $0.02 in 2025.
  • Its last three reported values are $0.02 in Q3 2025, $0.02 for Q2 2025, and $0.02 during Q1 2025.